Watch ARMP. Know when insiders buy.
One email the day a filing lands. Free.
ARMP
Armata Pharmaceuticals, Inc.
5.84
+0.32 +5.80%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
56
WATCH · shorts 56
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $217.1MP/E —DIV YIELD —FCF YIELD -11.88%REV TTM —NET INCOME −$192.2MNET CASH —52W 2.82 – 14.80SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$10.3M | $74.1M | — | -0.27 | −$8.7M | $17K | −$8.7M | Aug 12 |
| Q1 2026 · Mar 31 | — | — | — | −$8.8M | −$115.3M | — | -3.16 | −$5.8M | $63K | −$5.8M | May 13 |
| Q4 2025 · Dec 31derived | — | — | — | −$13.8M | −$124.3M | −4880.7% | -3.43 | −$6.7M | $52K | −$6.7M | Mar 25 |
| Q3 2025 · Sep 30 | — | — | — | −$7.8M | −$26.7M | — | -0.74 | −$4.3M | $242K | −$4.5M | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$6.8M | −$16.3M | −281.3% | -0.45 | −$7.2M | $149K | −$7.4M | Aug 12 |
| Q1 2025 · Mar 31 | — | — | — | −$8.2M | −$6.5M | — | -0.20 | −$7.6M | $99K | −$7.7M | May 13 |
| Q4 2024 · Dec 31derived | — | — | — | −$10.5M | $2.6M | — | -0.29 | −$7.9M | −$77K | −$7.8M | Mar 25 |
| Q3 2024 · Sep 30 | — | — | — | −$9.8M | −$5.5M | — | -0.15 | −$8.9M | $340K | −$9.2M | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$11.9M | $9M | — | -0.25 | −$10.2M | $1.4M | −$11.5M | Aug 12 |
| Q1 2024 · Mar 31 | — | — | — | −$10.2M | −$25M | — | -0.69 | −$10.6M | $250K | −$10.8M | Aug 12 |
| Q4 2023 · Dec 31derived | — | — | — | −$9.6M | −$19.8M | — | -0.55 | −$8.1M | $2.4M | −$10.5M | Mar 21 |
| Q3 2023 · Sep 30 | — | — | — | −$10.3M | −$31.2M | — | -0.86 | −$9.7M | $3.5M | −$13.2M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$36.6M | −$173.8M | — | -4.80 | −$25.8M | $542K | −$26.3M | — | — |
| FY2024 · to Dec 31 | — | — | −$42.4M | −$18.9M | — | -0.89 | −$37.6M | $1.9M | −$39.4M | — | — |
| FY2023 · to Dec 31 | — | — | −$40.9M | −$69M | — | -1.91 | −$47.4M | $8.1M | −$55.6M | — | — |
| FY2022 · to Dec 31 | — | — | −$36.9M | −$36.9M | — | -1.08 | −$32.5M | $2.2M | −$34.7M | — | — |
| FY2021 · to Dec 31 | — | — | −$23.8M | −$23.2M | — | -0.96 | −$23.6M | $1.3M | −$24.9M | — | — |
| FY2020 · to Dec 31 | — | — | −$21.6M | −$22.2M | — | -1.35 | −$18.3M | $824K | −$19.1M | — | — |
Every number comes from Armata Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.